-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The National Institute for Health and Clinical Excellence (NICE) recommends Sanofi's CD38 monoantigen Sarclisa and pomalidomide and desemison xamethasone, pom-dex) is used in adult patients who have received three previous therapies and at least two previous therapies include recurring/refractic multiple myeloma of lysamine and protease inhibitors.
multiple myeloma (Photo: pharmaLive) The recommendation is based on data from the ICARIA-MM trial, which demonstrated that Sarclisa plus pom-dex reduced the risk of disease progression or death by 40 percent in adult patients.
the combined treatment extended the progress-free life to 11.5 months compared to 6.5 months at the time of treatment using pom-dex alone.
, Sarclisa extended the non-progressing lifetime by 5.0 months.
also found good tolerance for adding Sarclisa to pom-dex, and there was no increase in the occurrence of treatment interruptions or fatal events compared to the pom-dex group.
cd38 single resistance principle (Photo: CD38: A Target for Immunotherapeutic Ideas in Multiple Myeloma. Front Immunol. 2018) In the UK, about 5,700 people are diagnosed with multiple myeloma each year, and there are more than 3,000 deaths associated with multiple myeloma each year.
patients often experience frequent relapses, and patients gradually develop resistance to multiple therapies.
.
